Results show dosing intervals increasing by two weeks or longer for patients with diabetic macular edema and neovascular (wet) age-related macular degeneration who switch to Eylea HD.

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.